DrugTargetSeqR: a genomics- and CRISPR/Cas9-based method to analyze drug targets

To identify the physiological targets of drugs and bioactive small molecules we have developed an approach, named DrugTargetSeqR, which combines high-throughput sequencing, computational mutation discovery and CRISPR/Cas9-based genome editing. We apply this approach to ispinesib and YM155, drugs that have undergone clinical trials as anti-cancer agents, and demonstrate target identification and uncover genetic and epigenetic mechanisms likely to cause drug resistance in human cancer cells.

[1]  Hanlee P. Ji,et al.  Next-generation DNA sequencing , 2008, Nature Biotechnology.

[2]  J. Adams.  The development of proteasome inhibitors as anticancer drugs. , 2004, Cancer cell.

[3]  Le Cong,et al.  Multiplex Genome Engineering Using CRISPR/Cas Systems , 2013, Science.

[4]  S. Haggarty,et al.  Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. , 1999, Science.

[5]  R. Ohi,et al.  Kinesin-12 Differentially Affects Spindle Assembly Depending on Its Microtubule Substrate , 2013, Current Biology.

[6]  M. Stratton,et al.  The cancer genome , 2009, Nature.

[7]  David Holmes.  Cancer drug's survivin suppression called into question , 2012, Nature Medicine.

[8]  K. Wood,et al.  Antitumor activity of a kinesin inhibitor. , 2004, Cancer research.

[9]  J. Ellenberg,et al.  EGF-induced centrosome separation promotes mitotic progression and cell survival. , 2013, Developmental cell.

[10]  S. Mackay,et al.  Mitotic kinesin Eg5 overcomes inhibition to the phase I/II clinical candidate SB743921 by an allosteric resistance mechanism. , 2013, Journal of medicinal chemistry.

[11]  Hans Clevers,et al.  Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. , 2013, Cell stem cell.

[12]  P. Clemons,et al.  Target identification and mechanism of action in chemical biology and drug discovery. , 2013, Nature chemical biology.

[13]  Andrew R. Bassett,et al.  Mutagenesis and homologous recombination in Drosophila cell lines using CRISPR/Cas9 , 2013, Biology Open.

[14]  James E. DiCarlo,et al.  RNA-Guided Human Genome Engineering via Cas9 , 2013, Science.

[15]  William A Weiss,et al.  Recognizing and exploiting differences between RNAi and small-molecule inhibitors. , 2007, Nature chemical biology.

[16]  Makoto Kinoshita,et al.  [Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen]. , 2007, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[17]  Michael T. McManus,et al.  A Systematic Mammalian Genetic Interaction Map Reveals Pathways Underlying Ricin Susceptibility , 2013, Cell.

[18]  J. Scholey,et al.  A "slow" homotetrameric kinesin-related motor protein purified from Drosophila embryos. , 1994, The Journal of biological chemistry.

[19]  Olivier Elemento,et al.  Using transcriptome sequencing to identify mechanisms of drug action and resistance , 2011, Nature chemical biology.

[20]  Jun O. Liu,et al.  Identification and validation of protein targets of bioactive small molecules. , 2012, Bioorganic & medicinal chemistry.

[21]  K. Brejc,et al.  Mitotic kinesins: prospects for antimitotic drug discovery. , 2005, Current topics in medicinal chemistry.

[22]  Neville E. Sanjana,et al.  Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells , 2014, Science.

[23]  Oliver Rath,et al.  Kinesins and cancer , 2012, Nature Reviews Cancer.

[24]  Jeffrey C. Miller,et al.  A rapid and general assay for monitoring endogenous gene modification. , 2010, Methods in molecular biology.

[25]  D. Newton,et al.  The “survivin suppressants” NSC 80467 and YM155 induce a DNA damage response , 2012, Cancer Chemotherapy and Pharmacology.

[26]  E. Lander,et al.  Genetic Screens in Human Cells Using the CRISPR-Cas9 System , 2013, Science.